# Access Consortium

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed August 9, 2026.

> The Access Consortium is an international collaboration among regulatory authorities from the UK, Australia, Canada, Singapore, and Switzerland. It aims to streamline the market authorization process for new active substances (NASWSI) and biosimilars (BSWSI) by facilitating work-sharing assessment procedures, reducing duplication, and promoting regulatory cooperation.

- Business Profile: https://optimly.ai/brand/access-consortium
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://accessconsortium.info/
- Logo: https://logo.clearbit.com/accessconsortium.info
- Slug: access-consortium
- Brand Authority Index tier: Low Visibility
- Archetype: Incumbent
- Category: Regulatory Affairs
- Last Analyzed: August 9, 2026

## Buyer Intent Signals
Problems: Individual National Regulatory Submissions: Instead of participating in the Access Consortium's work-sharing, a pharmaceutical company could opt to submit full, independent applications to each nation | Regulatory Affairs Consultancy Services: Companies can engage specialized regulatory affairs consultancies to manage and navigate the complexities of multi-jurisdictional drug approval processes, whet | Limited Market Authorization Scope: A company might choose to limit the market authorization of its new active substance or biosimilar to fewer countries, or only a single primary market, to avoid the
Solutions: Access Consortium New Active Substance Work-Sharing | Access Consortium biosimilar application process | NASWSI operational procedures | How to apply for Access Consortium | Access Consortium participating countries
---
## Full Details / RAG Data
### Overview
Access Consortium has a Business Profile in the Optimly AI Brand Index.
The Access Consortium is an international collaboration among regulatory authorities from the UK, Australia, Canada, Singapore, and Switzerland. It aims to streamline the market authorization process for new active substances (NASWSI) and biosimilars (BSWSI) by facilitating work-sharing assessment procedures, reducing duplication, and promoting regulatory cooperation.
### Metadata
| Field        | Value |
|--------------|-------|
| Name         | Access Consortium |
| Slug         | access-consortium |
| URL          | https://optimly.ai/brand/access-consortium |
| Logo         | https://logo.clearbit.com/accessconsortium.info |
| Brand Authority Index tier | Low Visibility |
| Archetype    | Incumbent |
| Category     | Regulatory Affairs |
| Last Analyzed | August 9, 2026 |
| Last Updated | 2026-08-11T15:39:03.753Z |
### Verified Facts
- Headquarters: International (comprising multiple national regulatory authorities)
### Buyer Intent Signals
#### Problems this brand solves
- Individual National Regulatory Submissions: Instead of participating in the Access Consortium's work-sharing, a pharmaceutical company could opt to submit full, independent applications to each nation
- Regulatory Affairs Consultancy Services: Companies can engage specialized regulatory affairs consultancies to manage and navigate the complexities of multi-jurisdictional drug approval processes, whet
- Limited Market Authorization Scope: A company might choose to limit the market authorization of its new active substance or biosimilar to fewer countries, or only a single primary market, to avoid the
#### Buyers search for
- Access Consortium New Active Substance Work-Sharing
- Access Consortium biosimilar application process
- NASWSI operational procedures
- How to apply for Access Consortium
- Access Consortium participating countries
### Links
- Canonical page: https://optimly.ai/brand/access-consortium
- Official website: https://accessconsortium.info/
- Publisher: https://optimly.ai
- Dataset: https://optimly.ai/brand
- JSON endpoint: /brand/access-consortium.json
- LLMs.txt: /brand/access-consortium/llms.txt